A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Recurrent or Metastatic Nasopharyngeal Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Chongqing University Cancer Hospital, Chongqing, Chongqing Municipality, China

  • Fujian Cancer Hospital, Fuzhou, Fujian, China

  • The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China

  • Zhangzhou Municiple Hospital of Fujian Province, Zhangzhou, Fujian, China

  • Dongguan People's Hospital, Dongguan, Guangdong, China

  • Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, Guangdong, China

  • Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China

  • Jiangmen Central Hospital, Jiangmen, Guangdong, China

  • Yuebei People's Hospital, Shaoguan, Guangdong, China

  • The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China

  • Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China

  • The First Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China

  • Hunan Cancer Hospital, Changsha, Hunan, China

  • Jiangxi Cancer Hospital, Nanchang, Jiangxi, China

  • The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China

  • Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality, China

  • Sichuan Cancer Hospital, Chengdu, Sichuan, China

  • Yunnan Cancer Hospital, Kunming, Yunnan, China

  • Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China